ABSTRACT
Objectives: The US is amid a national opioid crisis before and during the COVID-19 pandemic. The Food and Drug Administration has approved methadone, buprenorphine, and naltrexone as medications for opioid use disorder (MOUD). This study examined the real-world dispensing of MOUD. Methods: All dispensing pharmacies, clinics, or other dispensers of Schedule II-V controlled substances in California report to the Controlled Substance Utilization Review and Evaluation System (CURES) on the day of prescriptions refills. Leveraging the data of buprenorphine (schedule III) and methadone (Schedule II) prescriptions from Mar 2019-Mar 2021 employing California’s deidentified CURES database, this study examined real-world dispensing of methadone and buprenorphine before (03/19/2019-03/18/2020) and during the pandemic (03/19/2020-03/18/2021). We did not review naltrexone dispensing, which is not a controlled substance. Results: In Mar 2019-Mar 2021, 182,367 patients≥18 in California obtained 875,051 buprenorphine and methadone prescriptions: Before the pandemic, there were 482,965 MOUD prescriptions dispensed to 116,644 patients;since the pandemic, 97,887 patients received 392,086 prescriptions, of which 32,164 patients(as “non-naïve” patients) started their MOUD before Mar 2020. On average, patients refilled their prescriptions 4.1 times/year before the pandemic and 4.0 times/year since the pandemic. The MOUD non-naïve patients (n=32,164) received 8.1 prescriptions/year before Mar 2020 and 7.4 refills/year afterward. The MOUD medications most widely prescribed in Mar 2019-Mar 2021 were buprenorphine (473,206 (98.0%) and 383,297 (97.8%), respectively, before and after the pandemic), which included 802,936 counts of buprenorphine alone and 53,567 combination medications of buprenorphine and naloxone. The number of methadone prescriptions declined from 9,759 before Mar 2020 to 8,789 during the pandemic. Conclusions: Buprenorphine is the leading MOUD prescribed for patients in California. The decline in MOUD dispensing for non-naïve patients may indicate restricted access to medication-assisted treatment under the pandemic. Policymakers should maintain or modify the policy strategies to help support medication access.